Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: Entrée for resoleomics

Rheumatic Disease Clinics of North America

Volumn 30, Issue 1, 2004, Pages 69-95

  Serhan, Charles N ^a   Chiang, Nan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; AUTACOID; CANNABINOID RECEPTOR; DEXAMETHASONE; DEXTRAN; DICLOFENAC; EPOXIDE; FLAVONOID; GLUCOCORTICOID; INDOMETACIN; LEUKOTRIENE B4; LIPID; LIPOPOLYSACCHARIDE; LIPOXIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL MODEL; ATHEROSCLEROSIS; BIOSYNTHESIS; CELL INTERACTION; CELL PROLIFERATION; CELL TYPE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOTHELIUM; EOSINOPHIL; EPITHELIUM CELL; GENE EXPRESSION; HOST CELL; HUMAN; INFLAMMATION; INTESTINE CELL; LEUKOCYTE; MACROPHAGE; MEDIATOR RELEASE; MOLECULAR CLONING; MOLECULE; NEOPLASM; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; SIGNAL TRANSDUCTION; STIMULUS RESPONSE;

EID: 1242340404     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00117-0     Document Type: Review

References (72)

1. Cotran R.S., Kumar V., Collins T. Robbins pathologic basis of disease. 6th edition:1999;W.B. Saunders Co. Philadelphia.
2. Serhan C.N. Endogenous chemical mediators in anti-inflammation and pro-resolution. Curr Med Chem. 1:2002;177-192.
3. Nathan C. Points of control in inflammation. Nature. 420:2002;846-852.
4. Samuelsson B., Dahlén S.E., Lindgren J.Å., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237:1987;1171-1176.
5. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 192:2000;1197-1204.
6. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med. 196:2002;1025-1037.
7. 4. FASEB J. 13:1999;903-911.
8. Levy B.D., Petasis N.A., Serhan C.N. A role for polyisoprenyl phosphates in intracellular signaling. Nature. 389:1997;985-990.
9. Qiu F.-H., Wada K., Stahl G.L., Serhan C.N. IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proc Natl Acad Sci USA. 97:2000;4267-4272.
10. Liaudet L., Mabley J.G., Pacher P., Virag L., Soriano F.G., Marton A.et al. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg. 235:2002;568-578.
11. Hasko G., Kuhel D.G., Nemeth Z.H., Mabley J.G., Stachlewitz R.F., Virag L.et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol. 164:2000;1013-1019.
12. 4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med. 186:1997;1401-1406.
13. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 41:2001;775-787.
14. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
15. Pitzalis C., Pipitone N., Perretti M. Regulation of leukocyte- endothelial interactions by glucocorticoids. Ann N Y Acad Sci. 966:2002;108-118.
16. Serhan C.N. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta. 1212(1):1994;1-25.
17. Marcus A.J. Aspirin as prophylaxis against colorectal cancer. N Engl J Med. 333:1995;656-658.
18. Vane J.R. 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin. les Prix Nobel: Nobel Prizes, presentations, biographies and lectures. 1982;181-206 Almqvist & Wiksell, Stockholm (Sweden).
19. Clària J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA. 92:1995;9475-9479.
20. Schottelius A.J., Giesen C., Asadullah K., Fierro I.M., Colgan S.P., Bauman J.et al. An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol. 169:2002;7063-7070.
21. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry. 34:1995;14609-14615.
22. Cronstein B.N., Montesinos M.C., Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB. Proc Natl Acad Sci USA. 96:1999;6377-6381.
23. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins. 53:1997;107-137.
24. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2:2001;612-619.
25. Samuelsson B. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. Les Prix Nobel: Nobel Prizes, presentations, biographies and lectures. 1982;153-174 Almqvist & Wiksell, Stockholm (Sweden).
26. Levy G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 11:1997;234-247.
27. 4 metabolic inactivation. J Biol Chem. 275:2000;25372-25380.
28. 4 analogs with increased biologic activity. FASEB J. 12:1998;487-494.
29. +)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun. 276:2000;77-81.
30. +-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Arch Biochem Biophys. 405:2002;247-251.
31. Clish C.B., Sun Y.P., Serhan C.N. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. Biochem Biophys Res Commun. 288(4):2001;868-874.
32. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA. 96:1999;8247-8252.
33. Munger K.A., Montero A., Fukunaga M., Uda S., Yura T., Imai E.et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA. 96:1999;13375-13380.
34. 4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J Immunol. 164:2000;1029-1036.
35. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest. 104:1999;309-316.
36. Aliberti J., Serhan C., Sher A. Parasite-induced lipoxin A(4) is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med. 196:2002;1253-1262.
37. Aliberti J., Hieny S., Reis e Sousa C., Serhan C.N., Sher A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol. 3:2002;76-82.
38. 4. Nat Med. 8:2002;1018-1023.
39. 4 ELISA. J Pharmacol Exp Ther. 287:1998;779-790.
40. Perretti M., Chiang N., La M., Fierro I.M., Marullo S., Getting S.J.et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A(4) receptor. Nat Med. 8:2002;1296-1302.
41. 4 (ATL). Am J Physiol. 277:1999;C870-C877.
42. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology. 123:2002;1598-1606.
43. 4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry. 39:2000;4761-4768.
44. Bonnans C., Vachier I., Chavis C., Godard P., Bousquet J., Chanez P. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med. 165:2002;1531-1535.
45. Sanak M., Levy B.D., Clish C.B., Chiang N., Gronert K., Mastalerz L.et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J. 16:2000;44-49.
46. Mitchell S., Thomas G., Harvey K., Cottell D., Reville K., Berlasconi G.et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol. 13:2002;2497-2507.
47. 4 receptor that is conserved in structure and function. Br J Pharmacol. 139:2003;89-98.
48. 4, is protective in experimental ischemic acute renal failure. J Am Soc Nephrol. 13:2002;1657-1662.
49. 4. J Pharmacol Exp Ther. 300:2002;385-392.
50. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol. 168:2002;5260-5267.
51. Gavins F.N., Yona S., Kamal A.M., Flower R.J., Perretti M. Leukocyte anti-adhesive actions of annexin 1: ALXR and FPR related anti-inflammatory mechanisms. Blood. 101:2003;4140-4147.
52. Jozsef L., Zouki C., Petasis N.A., Serhan C.N., Filep J.G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA. 99:2002;13266-13271.
53. 4 stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood. 94:1999;4132-4142.
54. Godson C., Mitchell S., Harvey K., Petasis N.A., Hogg N., Brady H.R. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol. 164:2000;1663-1667.
55. 4 block allergen-induced eosinophil trafficking. J Immunol. 164:2000;2267-2271.
56. 4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol. 164:2000;2660-2666.
57. 4 in human renal mesangial cells: differential activation of MAP kinases through distinct receptors. J Biol Chem. 275:2000;27566-27575.
58. 4. FASEB J. 16:2002;1937-1939.
59. Devchand P.R., Arita M., Hong S., Bannenberg G., Moussignac R.-L., Gronert K.et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host-defense. FASEB J. 17:2003;652-659.
60. 4 receptor that is regulated by IL-13 and IFN-γ and inhibits TNF-α-induced IL-8 release. J Exp Med. 187:1998;1285-1294.
61. 4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy. 49:1994;230-234.
62. 4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med. 191:2000;1197-1207.
63. Resnati M., Pallavicini I., Wang J.M., Oppenheim J.J., Serhan C.N., Romano M.et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 99:2002;1359-1364.
64. Le Y., Murphy P.M., Wang J.M. Formyl-peptide receptors revisited. Trends Immunol. 23:2002;541-548.
65. Maderna P., Cottell D.C., Berlasconi G., Petasis N.A., Brady H.R., Godson C. Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am J Pathol. 160:2002;2275-2283.
66. 4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J. 15:2001;2736-2738.
67. Canny G., Levy O., Furuta G.T., Narravula-Alipati S., Sisson R.B., Serhan C.N.et al. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA. 99:2002;3902-3907.
68. 4 analogs. J Clin Invest. 101:1998;1860-1869.
69. Maderna P., Godson C., Hannify G., Murphy M., Brady H.R. Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression. Am J Physiol Cell Physiol. 279:2000;C945-C953.
70. 4 receptors. J Exp Med. 192:2000;F5-F8.
71. Hong S., Gronert K., Devchand P., Moussignac R.-L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem. 278:2003;14677-14687.
72. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433-442.